Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...
Eli Lilly & Co. CEO Dave Ricks says the U.K. has gone from biopharmaceutical leader to laggard. Lilly is among a handful of biopharma companies that have put investments in the U.K. on hold amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results